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Introduction: Limited data is available on the rates of bleeding and thromboembolic events for patients under
going low bleeding risk procedures while taking direct oral anticoagulants (DOAC).
Methods: Adults taking DOAC in the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) database
who underwent a low bleeding risk procedure between May 2015 and Sep 2019 were included. Thirty-day
bleeding (of any severity), thromboembolic events, and death were compared between DOAC temporarily
interrupted and continued uninterrupted groups. Adverse event rates were compared using an inverse proba
bility weighting propensity score.
Results: There were 820 patients who underwent 1412 low risk procedures. DOAC therapy was temporarily
interrupted in 371 (45.2%) patients (601 [42.6%] procedures) and continued uninterrupted in 449 (54.8%)
patients (811 [57.4%] procedures). DOAC patients with temporary interruptions were more likely to have
diabetes, prior stroke or TIA, prior bleeding, higher CHA2DS2-VASc, and higher modified HAS-BLED scores.
DOAC interruption was common for gastrointestinal endoscopy, electrophysiology device implantation, and
cardiac catheterization while it was less common for cardioversion, dermatologic procedures, and subcutaneous
injection. After propensity score adjustment, bleeding risk was lower in the DOAC temporary interruption group
(OR 0.62, 95% CI 0.41–0.95) as compared to the group with continuous DOAC use. Rates of thromboembolic
events and death did not differ significantly between the two groups.
Conclusions: DOAC-treated patients undergoing low bleeding risk procedures may experience lower rates of
bleeding when DOAC is temporarily interrupted. Prospective studies focused on low bleeding risk procedures are
needed to identify the safety DOAC management strategy.

1. Introduction
Atrial fibrillation (AF) and venous thromboembolism (VTE) are
major health problems in the United States with an estimated 1.2 million
cases of AF in 2010 and 1 million VTE events occurring in 2014 alone
[1]. Anticoagulation used in these patients to prevent thromboembolic
complications also increases the risk of bleeding [2]. Since 2009, the

direct oral anticoagulants (DOAC) have gained prominence and are now
increasingly used as compared to warfarin [3].
In preparation for surgical or invasive procedures, patients often
require a temporary interruption of the anticoagulant to reduce periprocedural bleeding risk [4]. For certain lower bleeding risk proced
ures, such as pacemaker implantation or ablation of atrial fibrillation,
randomized trial data in both warfarin- and DOAC-treated patients
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Fig. 1. Standardized difference plot before and after inverse probability weighting.

suggests safety and efficacy when the anticoagulant is continued unin
terrupted [5–11]. While peri-procedural anticoagulation management
for electrophysiology (EP) procedures has been fairly well studied,
limited data is available to compare temporary interruption versus
routine continuation of DOAC medications for other low bleeding risk
procedures. We aimed to describe rates of bleeding and thromboembolic
events for patients undergoing low bleeding risk procedures while tak
ing DOAC medications.

Boards at the University of Michigan (coordinating center) and at each
participating site. [12–14]
2.1. Patient selection
From the MAQI2 DOAC registry, we identified adult patients taking
DOAC medications at the four participating sites who underwent a low
bleeding risk procedure between May 2015 to September 2019. Low
bleeding risk procedures included: biopsy (e.g. bone marrow, thyroid,
endometrial), bronchoscopy, cardiac ablation, cardiac catheterization,
cardioversion, cutaneous incision and drainage, cystoscopy, dental
procedure, dermatologic procedure, electrophysiology device implan
tation, gastrointestinal (GI) endoscopy, ophthalmologic procedure,
peripherally inserted central catheter placement, port placement/
removal, subcutaneous injection, and other surgery/procedure lasting
<1 h (procedures not categorized into any of the previous groups with
duration less than 1 h). This criteria was initially developed based on
similar criteria used in the BRIDGE (Perioperative Bridging Anti
coagulation in Patients with Atrial Fibrillation) trial [15].
Patients on heparin or low molecular weight heparin (LMWH)
bridging, and those undergoing moderate- or high-bleeding risk pro
cedure were excluded.

2. Methods
Patients taking DOAC therapy were identified from four hospitals
participating in the Michigan Anticoagulation Quality Improvement
Initiative (MAQI2). MAQI2 is a Blue Cross Blue Shield of Michigan/Blue
Care Network (BCBSM/BCN)-funded collaborative of hospitals- or group
practice-affiliated anticoagulation services across the state of Michigan.
Beginning in 2015, patients initiated on DOAC therapy at a participating
MAQI2 center were eligible for enrollment in the MAQI2 database. Pa
tients were randomly selected monthly for enrollment into the registry.
During the study period, MAQI2 had no impact on anticoagulant man
agement decisions, which were made by the primary providers. Data
abstractors undergo standardized training and participating sites un
dergo regular audits to ensure that abstracted data is accurate and
concordant with pre-set clinical definitions. Major clinical events
(including stroke, systemic embolism and major bleeding events) un
dergo audit by the coordinating center. Use of the MAQI2 registry is
approved with a waiver of informed consent by the Institutional Review

2.2. Data collection
Since patients may undergo multiple procedures with different periprocedural anticoagulation management for each procedure, analysis
28
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Table 1
Demographic comparison between DOAC temporarily interrupted and continued uninterrupted groups.
Demographics

DOAC temporarily interrupted
N = 371

DOAC continued uninterrupted
N = 449

Standardized difference
Unweighted

Unweighted

Age
Male Gender
Hypertension
Heart Failure
Diabetes Mellitus
Prior Stroke or TIA
CAD, PAD or Aortic plaque
Chronic Liver Disease or Cirrhosis
Chronic Renal Insufficiency
Heavy Alcohol Use
Malignancy
Thrombocytopeniaa
Severe Thrombocytopeniab
Anemiac
Prior Bleeding Event
History of Falls
Bleeding diathesis
Hypercoagulable state
Drugsd
CHA2DS2-VASc score
Modified HAS-BLED Score
Apixaban
Rivaroxaban
Dabigatran
Edoxaban

69.9 ± 12.6
206 (55.5%)
284 (76.6%)
84 (22.6%)
112 (30.2%)
64 (17.3%)
122 (32.9%)
20 (5.4%)
65 (17.5%)
28 (7.6%)
115 (31.0%)
44 (11.9%)
2 (0.54%)
150 (40.4%)
186 (50.1%)
47 (12.7%)
0
5 (1.4%)
130 (35.0%)
3.5 ± 1.9
2.8 ± 1.4
258 (69.6%)
107 (28.8%)
6 (1.6%)
0

69.7 ± 12.8
255 (56.8%)
334 (74.4%)
94 (20.9%)
101 (22.5%)
43 (9.6%)
129 (28.7%)
22 (4.9%)
56 (12.5%)
31 (6.9%)
138 (30.7%)
54 (12.0%)
4 (0.89%)
112 (25.1%)
150 (33.4%)
44 (9.8%)
2 (0.45%)
6 (1.3%)
129 (28.7%)
3.2 ± 1.8
2.4 ± 1.2
289 (64.4%)
154 (34.3%)
5 (1.1%)
1 (0.22%)

0.0166
− 0.0543
0.0936
0.0139
− 0.0650
− 0.2129
0.1555
− 0.0108
− 0.1692
0.0516
− 0.0762
− 0.0510
0.0220
− 0.2365
− 0.1955
0.1174
–
0.0478
− 0.2234
0.1895
0.3271
0.1253
− 0.1256
0.0081
–

0.0166
− 0.0543
0.0936
0.0139
− 0.0650
− 0.2129
0.1555
− 0.0108
− 0.1692
0.0516
− 0.0762
− 0.0510
0.0220
− 0.2365
− 0.1955
0.1174
–
0.0478
− 0.2234
0.1895
0.3271
0.1253
− 0.1256
0.0081
–

Abbreviations: TIA = transient ischemic attack; CAD = coronary artery disease; PAD = peripheral arterial disease; NSAIDs = nonsteroidal anti-inflammatory drugs;
CHA2DS2-VASc = congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex
category; HAS-BLED = hypertension, abnormal renal and liver function, stroke, bleeding, labile INR (excluded), elderly, drugs or alcohol.
a
Platelet count of <150,000/L.
b
Platelet count of <50,000/L.
c
Hemoglobin <13 g/dL for Men and < 12 g/dL for Women.
d
Use of aspirin, clopidogrel, prasugrel, ticagrelor or NSAIDs.

was based on the procedure- rather than the patient-level. Procedures
were categorized based on DOAC management, namely if DOAC medi
cations were temporarily interrupted or continued uninterrupted. This
information is obtained by data abstractors during chart review. The
decision of peri-procedural interruption or continuation was made by
the primary providers, typically without input from the anticoagulation
clinic or research team. Therefore, no details about reasons for DOAC
interruption or continuation are available for analysis.
Determination of continuation or interruption of DOAC was made by
reviewing all available provider notes in the electronic medical record.
We defined interruption as at least one missed dose of DOAC prior to
procedure. If periprocedural anticoagulation management was not clear
after thorough chart review, the DOAC status around the procedure was
recorded as “unknown”. The procedures for which DOAC continuation
or interruption was unknown were excluded. Of the 2259 total pro
cedures in the database, 239 had unknown DOAC continuation or
interruption status which were excluded. Of the 2020 total procedures
with known DOAC status 1412 were low-risk procedures.

2.4. Statistical analysis
For baseline group comparisons, standardized differences were used
(Fig. 1) Adverse events were compared by Poisson test and reported as
95% confidence interval (CI) of difference. To adjust for measured po
tential confounders, we used an inverse probability weighted regression
adjustment approach. A propensity model with clinical and de
mographic elements listed in Table 1 and Fig. 1 was used to calculate
inverse probability weight in two groups, namely diabetes, prior stroke
or TIA, renal disease, anemia, prior bleeding event, drug use (aspirin,
clopidogrel, prasugrel, ticagrelor or NSAIDs) and procedure type, and
modified HAS-BLED score [18] [without labile INR (International
Normalized Ratio)]. A logistic model was preformed based on inverse
probability weights, to model outcomes adjusted by significant clinical
and demographic elements. Results were reported as odds ratio with
their 95% confidence intervals. Standardized weights before adjustment
and after inverse probability weighting are shown in Fig. 1. A two-sided
P < 0.05 was considered statistically significant for all analyses. Ana
lyses were performed with statistical software SAS version 9.4 (Cary,
NC) and R version 3.3.1.

2.3. Outcomes
Thirty-day bleeding events, thromboembolic events, and death were
compared between the interrupted and uninterrupted groups. All events
were abstracted from the medical chart by trained abstractors using prespecified data forms and definitions. Bleeding was characterized as
major, clinically relevant non-major (CRNM), or minor according to the
International Society of Thrombosis and Hemostasis (ISTH) consensus
definitions [16,17]. Bleeding events of any severity (major, minor and
CRNM) were grouped and reported as ‘any bleeding.’ Stroke and sys
temic embolism were defined according to physician diagnosis or
discharge diagnosis and abstracted into the registry.

3. Results
There were 820 patients who underwent 1412 low risk procedures.
Atrial fibrillation was indication for anticoagulation for the majority:
1069 AF, 278 VTE, and 1 for AF and VTE. DOAC therapy was tempo
rarily interrupted in 371 (45.2%) patients (601 [42.6%] procedures) and
continued in 449 (54.8%) patients (811 [57.4%] procedures). Apixaban,
rivaroxaban, dabigatran and rivaroxaban were the DOAC medications
included.
As shown in Table 1, procedures where a patient’s DOAC was
temporarily interrupted were more likely to occur in patients with
29
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Table 2
DOAC interruption and continuation for each procedure.
Procedure

Total

Table 3
Low dose DOAC use.

DOAC temporarily
interrupted

DOAC continued
uninterrupted

N (%)

Bleeding
N (%)

N (%)

Bleeding
N (%)

223
(84.50)
42
(79.20)

19 (8.52)

41
(15.50)
11
(20.80)

2 (4.88)

83
(79.00)
85
(61.60)
14
(58.33)
4
(57.14)
5
(50.00)
1
(50.00)
74
(48.10)

6 (7.23)

22
(21.00)
53
(38.40)
10
(41.67)
3
(42.86)
5
(50.00)
1
(50.00)
80
(51.90)

4 (18.18)

19

9
(47.37)

1 (11.11)

10
(52.63)

1 (10)

72

15
(20.80)

3 (20)

57
(79.20)

0

80

13
(16.30)

0

67
(83.80)

1 (1.49)

129

17
(13.20)

3 (17.65)

112
(86.80)

11 (9.82)

40

5
(12.50)

0

35
(87.50)

5 (14.29)

313

9 (2.9)

1 (11.11)

304
(97.10)

14 (4.61)

Gastrointestinal
endoscopy
Permanent pacemaker
or internal
defibrillator insertion
or loop recorder
Cardiac catheterization

264

Cardiac Ablation

138

53

105

Dental surgery or other
dental procedure
Incision and Drainage

24

Port placement/
removal
Dilation and Curettage

10

Any other surgery or
procedure lasting less
than 1 h
Biopsy (e.g. bone
marrow, thyroid,
endometrial)
Cataract removal or
other
ophthalmologic
procedure
Injection (e.g.
cortisone,
dermatologic)
Dermatologic surgery
or other
dermatologic
procedure
Scoping (e.g.
bronchoscopy,
nasopharyngeal,
knee, cystosopy)
Cardioversion

154

7

2

7 (16.67)

9 (10.59)
1 (7.14)
0
2 (40)
0
4 (5.41)

Patient level (number
of patients)
On Low-dose DOACa
Procedure level
(number of
procedures)
On Low-dose DOACa

1 (9.09)

a

3 (5.66)
2 (20)

Total

DOAC temporarily
interrupted

DOAC continued
uninterrupted

820

371

449

64
(7.8%)
1412

29 (7.8%)

35 (7.8%)

601

811

105
(7.4%)

50 (8.3%)

55 (6.8%)

Rivaroxaban 10 mg daily or apixaban 2.5 mg twice daily.

Table 4
Unadjusted outcomes.

1 (33.33)

Outcomes (30 days postprocedure)

0
0

Primary
Any bleeding events
Major bleed
Minor bleed
CRNM bleeda
Any thromboembolic
events
Secondary
Death due to any cause

6 (7.5)

DOAC temporarily
interrupted
N = 601

DOAC continued
uninterrupted
N = 811

pValue

56 (9.3%)
9 (1.50%)
47 (7.82%)
19 (3.16%)
3 (0.50%)

51 (6.3%)
4 (0.49%)
47 (5.80%)
15 (1.85%)
4 (0.49%)

0.03
0.05
0.13
0.11
1

5 (0.83%)

2 (0.25%)

0.14

CRNM = clinically relevant non-major.
a
minor bleeds that resulted in ED visits/hospitalizations.

continued uninterrupted (Table 3).
Unadjusted analysis showed that procedures where a patient
temporarily interrupted DOAC therapy experienced more 30-day
bleeding events and higher incidence of death without a statistically
significant difference in thromboembolic events as compared to pro
cedures with continued DOAC use (Table 4). In adjusted analyses, the
risk of bleeding decreased when DOAC therapy was temporarily inter
rupted (OR 0.59, 95% CI 0.39–0.91), while risk of thromboembolic
events (OR 1.31, 95% CI 0.26–6.85) and death (OR 0.29, 95% CI
0.04–2.26) showed no statistically significant difference in the two
treatment groups. (Fig. 2).

diabetes (30.2% vs 22.5%), prior stroke or transient ischemic attack
(17.3% vs 9.6%), anemia (40.4% vs 25.1%), prior bleeding (50.1% vs
33.4%) and higher modified HAS-BLED scores (2.8 ± 1.4 vs 2.4 ± 1.2).
Patients with procedures where DOAC therapy was temporarily inter
rupted also had higher CHA2DS2-VASc scores (3.5 ± 1.9 vs 3.2 ± 1.8).
Use of different DOAC agents (apixaban, rivaroxaban, dabigatran and
edoxaban) was similar in both groups.: apixaban 69.6% vs 64.4% (p
0.12), rivaroxaban 28.8% vs 34.3% (p 0.09), dabigatran 1.6% vs 1.1% (p
0.56) and edoxaban 0% vs 0.22% respectively.
Procedures for which DOAC therapy was most likely to be tempo
rarily interrupted included gastrointestinal (GI) endoscopy (223/263,
84.5%), electrophysiology (EP) device implantation (42/53, 79.2%) and
cardiac catheterization (83/105, 79%). Procedures where DOAC was
most likely to be continued uninterrupted included cardioversion (304/
313, 97.1%), dermatologic procedures (112/129, 86.8%) and subcu
taneous injection (67/80, 83.8%) (Table 2).
A small proportion were on low-dose DOAC (defined as rivaroxaban
10 mg daily or apixaban 2.5 mg twice daily). Out of total 820 patients 64
(7.8%) were taking low-dose DOAC medication; the corresponding
numbers in the DOAC temporarily interrupted group were 29/371
(7.8%) and in the DOAC continued uninterrupted group 35/449 (7.8%).
At the procedure level also a small percentage were on low-dose DOAC:
105/1412 (7.4%) for all procedures, 50/601 (8.3%) for procedures were
DOAC was temporarily interrupted and 55/811 (6.8%) when DOAC was

4. Discussion
In this retrospective cohort study of peri-procedural DOAC man
agement in low bleeding risk procedures, temporary interruption of
DOAC medications compared to uninterrupted DOAC therapy showed
slightly decreased risk of any bleeding.
The largest study of head-to-head comparison of peri-procedural
DOAC interruption vs continuation is the BRUISE CONTOL-2 which
studied patients undergoing cardiac electrophysiology procedures [11].
Their rates of bleeding (hematoma) of around 5% for all hematomas and
2% for device pocket hematoma in both groups were lower than ours
(9% and 6%). A sub-study of the ARISTOTLE trial (apixaban vs. warfarin
for atrial fibrillation) reported on perioperative bleeding when apixaban
was continued uninterrupted. The most common procedures included
were somewhat similar to those we studied. Major bleeding occurred in
28 of 1752 (1.6%) of patients operated on when apixaban was continued
uninterrupted [19]. These both differ somewhat from the findings in our
study, which demonstrated lower bleeding risk when DOAC therapy is
temporarily interrupted. Both these studies focused on EP procedures for
atrial fibrillation whereas we included a wide variety of low bleeding
risk procedures (also including EP procedures) that is likely responsible
for the differing results. Moreover, due to unselected population of
DOAC-treated patients, and the retrospective data collection we likely
30
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Fig. 2. Inverse probability weighting-adjusted outcomes among DOAC temporarily interrupted vs. continued uninterrupted patients.

had a more heterogeneous patient population which also may explain
why our findings are different.
In our study, DOAC therapy was most likely to be temporarily
interrupted for GI endoscopy, EP device implantation, and cardiac
catheterization procedures. Risk of bleeding from a potential biopsy
during endoscopy and use of heparin during cardiac catheterization
likely explain the inclination to interrupt DOAC. However, temporary
interruption of DOAC therapy for EP device procedures is somewhat
surprising given the robust evidence in favor of uninterrupted continu
ation [5,7–11]. One potential explanation is that with limited DOAC
experience and lack of trust or availability in DOAC-specific reversal
agents, many clinicians will prefer to stop DOAC therapy and instead
initiate heparin. Some patients take low-dose direct oral anticoagulants
for long-term venous thromboembolism prevention and providers might
be more comfortable continuing this level of anticoagulation versus full
therapeutic dose surrounding low-risk procedures. We found that a
small percentage and similar number were on low-dose DOAC in both
groups at both patient and procedure level, hence it is not likely to be
related to the outcomes.
The recent PAUSE study (Perioperative Anticoagulation Use for
Surgery Evaluation) demonstrated relative safety and efficacy for a
simple perioperative DOAC interruption and resumption protocol for
patients undergoing elective procedures, which span the bleeding risk
spectrum from low to high [20]. Unlike this study we did not include
high bleeding risk procedures in our analysis. However, the low bleeding
risk procedures in PAUSE included common gastrointestinal procedures
(e.g., colonoscopy), cardiac procedures (e.g., permanent pacemaker
implantation or battery change, coronary artery angiography), dental
procedures, skin procedures, and eye procedures. These low-risk pro
cedures largely overlapped with those included in our study. Given our
observation that routine continuation of DOAC medications (compared
to temporary interruption) was associated with increased bleeding risk,
a standardized approach to temporary interruption of DOAC medica
tions when patients undergo low bleeding risk procedures may be useful.
This warrants further investigation in a prospective study.
An important strength of our study is that the MAQI2 cohort com
prises contemporary real-world patients receiving care in a variety of
anticoagulation clinics in both suburban and urban settings, and
therefore represents typical patients on anticoagulation in the commu
nity. Unlike administrative databases relying on diagnostic and billing
codes, our data is manually abstracted by trained personnel and inde
pendently audited to verify accurate assessment of comorbidities and
events. MAQI2 auditing ensures highly reliable data abstraction with few
patients lost to follow up. The study also has several limitations. As with
all retrospective studies, the effect of unmeasured confounding cannot
be ruled out even after the use of propensity score methods. Addition
ally, some adverse outcomes may not have been captured by our reg
istry, especially if patients presented to a different health care system.
However, if any adverse event was noted in their medical chart, even in
follow up with a primary care provider or other specialist, those events
would be identified and abstracted into the MAQI2 registry.

5. Conclusions
DOAC-treated patients undergoing low bleeding risk procedures may
have increased bleeding risk when DOAC therapy is continued unin
terrupted as compared to when it is temporarily interrupted.
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